265 related articles for article (PubMed ID: 21502249)
21. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
22. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
Souayah N; Nasar A; Suri MF; Qureshi AI
J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
[TBL] [Abstract][Full Text] [Related]
23. Assuring the quality, safety, and efficacy of DNA vaccines.
Robertson JS; Griffiths E
Methods Mol Med; 2006; 127():363-74. PubMed ID: 16988466
[TBL] [Abstract][Full Text] [Related]
24. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
25. Vaccine safety: current systems and recent findings.
Wharton M
Curr Opin Pediatr; 2010 Feb; 22(1):88-93. PubMed ID: 19952750
[TBL] [Abstract][Full Text] [Related]
26. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
Noah BA; Brushwood DB
J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
[TBL] [Abstract][Full Text] [Related]
27. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
28. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
[TBL] [Abstract][Full Text] [Related]
29. The identification of benefit in medical intervention: an overview and suggestions for process.
Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
[TBL] [Abstract][Full Text] [Related]
30. How drugs are developed and approved by the FDA: current process and future directions.
Ciociola AA; Cohen LB; Kulkarni P;
Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
[TBL] [Abstract][Full Text] [Related]
31. Postlicensure epidemiology of childhood vaccination: the Danish experience.
Hviid A
Expert Rev Vaccines; 2006 Oct; 5(5):641-9. PubMed ID: 17181438
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
[TBL] [Abstract][Full Text] [Related]
33. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee.
Peter G; des Vignes-Kendrick M; Eickhoff TC; Fine A; Galvin V; Levine MM; Maldonado YA; Marcuse EK; Monath TP; Osborn JE; Plotkin S; Poland GA; Quinlisk MP; Smith DR; Sokol M; Soland DB; Whitley-Williams PN; Williamson DE; Breiman RF
Pediatrics; 1999 Oct; 104(4 Pt 1):942-50. PubMed ID: 10506239
[TBL] [Abstract][Full Text] [Related]
34. Which pharmacovigilance for vaccines?
Le Louët H; Loupi E; Haramburu F;
Therapie; 2007; 62(3):241-7. PubMed ID: 17803893
[TBL] [Abstract][Full Text] [Related]
35. Missing data issues at the FDA Center for Biologics Evaluation and Research.
Scott JA; Hsu H
J Biopharm Stat; 2011 Mar; 21(2):196-201. PubMed ID: 21390996
[TBL] [Abstract][Full Text] [Related]
36. The unfinished business of U.S. drug safety regulation.
Evans BJ; Flockhart DA
Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457
[No Abstract] [Full Text] [Related]
37. FDA policy on unapproved drug products: past, present, and future.
Chhabra R; Kremzner ME; Kiliany BJ
Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
[TBL] [Abstract][Full Text] [Related]
38. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
39. Regulatory perspectives on data monitoring.
O'Neill RT
Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
[TBL] [Abstract][Full Text] [Related]
40. The Vaccine Safety Datalink project.
DeStefano F;
Pharmacoepidemiol Drug Saf; 2001; 10(5):403-6. PubMed ID: 11802585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
